The role of tumor-derived exosomes in tumor angiogenesis and tumor progression

1. Zaborowski MP, Balaj L, Breakefield XO, Lai CP. Extracellular Vesicles: Composition, Biological Relevance, and Methods of Study. Bioscience. 2015;65(8):783-97.10.1093/biosci/biv084 Search in Google Scholar

2. Ribeiro MF, Zhu H, Millard RW, Fan GC. Exosomes Function in Pro- and Anti-Angiogenesis. Curr Angiogenes. 2013;2(1):54-9.10.2174/22115528113020020001 Search in Google Scholar

3. Escola JM, Kleijmeer MJ, Stoorvogel W, Griffith JM, Yoshie O, Geuze HJ. Selective enrichment of tetraspan proteins on the internal vesicles of multivesicular endosomes and on exosomes secreted by human B-lymphocytes. J Biol Chem. 1998;273(32):20121-7.10.1074/jbc.273.32.20121 Search in Google Scholar

4. Heijnen HF, Schiel AE, Fijnheer R, Geuze HJ, Sixma JJ. Activated platelets release two types of membrane vesicles: microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and alpha-granules. Blood. 1999;94(11):3791-9.10.1182/blood.V94.11.3791 Search in Google Scholar

5. Lai RC, Arslan F, Lee MM, Sze NS, Choo A, Chen TS, et al. Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury. Stem Cell Res. 2010;4(3):214-22.10.1016/j.scr.2009.12.003 Search in Google Scholar

6. Li QL, Bu N, Yu YC, Hua W, Xin XY. Exvivo experiments of human ovarian cancer ascites-derived exosomes presented by dendritic cells derived from umbilical cord blood for immunotherapy treatment. Clin Med Oncol. 2008;2:461-7.10.4137/CMO.S776 Search in Google Scholar

7. Ma B, Ren J, Jiang HF, Jia J. [Antitumor activities against hepato-cellular carcinoma induced by bone marrow mesenchymal stem cells pulsed with tumor-derived exosomes]. Beijing Da Xue Xue Bao Yi Xue Ban. 2008;40(5):494-9. Search in Google Scholar

8. Thery C, Regnault A, Garin J, Wolfers J, Zitvogel L, Ricciardi-Castagnoli P, et al. Molecular characterization of dendritic cell-derived exosomes. Selective accumulation of the heat shock protein hsc73. J Cell Biol. 1999;147(3):599-610.10.1083/jcb.147.3.599 Search in Google Scholar

9. Yu S, Liu C, Su K, Wang J, Liu Y, Zhang L, et al. Tumor exosomes inhibit differentiation of bone marrow dendritic cells. J Immunol. 2007;178(11):6867-75.10.4049/jimmunol.178.11.6867 Search in Google Scholar

10. Zhang X, Wang X, Zhu H, Kranias EG, Tang Y, Peng T, et al. Hsp20 functions as a novel cardiokine in promoting angiogenesis via activation of VEGFR2. PLoS One. 2012;7(3):e32765.10.1371/journal.pone.0032765 Search in Google Scholar

11. Al-Nedawi K, Meehan B, Rak J. Microvesicles: messengers and mediators of tumor progression. Cell Cycle. 2009;8(13):2014-8.10.4161/cc.8.13.8988 Search in Google Scholar

12. Camussi G, Deregibus MC, Bruno S, Cantaluppi V, Biancone L. Exosomes/microvesicles as a mechanism of cell-to-cell communication. Kidney Int. 2010;78(9):838-48.10.1038/ki.2010.278 Search in Google Scholar

13. Wieckowski E, Whiteside TL. Human tumor-derived vs dendritic cell-derived exosomes have distinct biologic roles and molecular profiles. Immunol Res. 2006;36(1-3):247-54.10.1385/IR:36:1:247 Search in Google Scholar

14. Zhu H, Fan GC. Extracellular/circulating microRNAs and their potential role in cardiovascular disease. Am J Cardiovasc Dis. 2011;1(2):138-49. Search in Google Scholar

15. Burnier L, Fontana P, Kwak BR, Angelillo-Scherrer A. Cell-derived microparticles in haemostasis and vascular medicine. Thromb Haemost. 2009;101(3):439-51.10.1160/TH08-08-0521 Search in Google Scholar

16. Dignat-George F, Boulanger CM. The many faces of endothelial microparticles. Arterioscler Thromb Vasc Biol. 2011;31(1):27-33.10.1161/ATVBAHA.110.21812321160065 Search in Google Scholar

17. Martinez MC, Andriantsitohaina R. Microparticles in angiogenesis: therapeutic potential. Circ Res. 2011;109(1):110-9.10.1161/CIRCRESAHA.110.23304921700952 Search in Google Scholar

18. Rajagopal C, Harikumar KB. The Origin and Functions of Exosomes in Cancer. Front Oncol. 2018;8:66.10.3389/fonc.2018.00066586925229616188 Search in Google Scholar

19. Keller S, Ridinger J, Rupp AK, Janssen JW, Altevogt P. Body fluid derived exosomes as a novel template for clinical diagnostics. J Transl Med. 2011;9:86.10.1186/1479-5876-9-86311833521651777 Search in Google Scholar

20. Ludwig N, Yerneni SS, Razzo BM, Whiteside TL. Exosomes from HNSCC Promote Angiogenesis through Reprogramming of Endothelial Cells. Mol Cancer Res. 2018;16(11):1798-808.10.1158/1541-7786.MCR-18-035830042174 Search in Google Scholar

21. Nishida N, Yano H, Nishida T, Kamura T, Kojiro M. Angiogenesis in cancer. Vasc Health Risk Manag. 2006;2(3):213-9.10.2147/vhrm.2006.2.3.213199398317326328 Search in Google Scholar

22. Rajabi M, Mousa SA. The Role of Angiogenesis in Cancer Treatment. Biomedicines. 2017;5(2).10.3390/biomedicines5020034548982028635679 Search in Google Scholar

23. Koch AE, Distler O. Vasculopathy and disordered angiogenesis in selected rheumatic diseases: rheumatoid arthritis and systemic sclerosis. Arthritis Res Ther. 2007;9 Suppl 2:S3.10.1186/ar2187207288917767741 Search in Google Scholar

24. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 2004;64(11):3731-6.10.1158/0008-5472.CAN-04-007415172975 Search in Google Scholar

25. Izumi Y, Xu L, di Tomaso E, Fukumura D, Jain RK. Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature. 2002;416(6878):279-80.10.1038/416279b11907566 Search in Google Scholar

26. Winkler F, Kozin SV, Tong RT, Chae SS, Booth MF, Garkavtsev I, et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell. 2004;6(6):553-63.10.1016/S1535-6108(04)00305-8 Search in Google Scholar

27. Yuan F, Chen Y, Dellian M, Safabakhsh N, Ferrara N, Jain RK. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci U S A. 1996;93(25):14765-70.10.1073/pnas.93.25.14765 Search in Google Scholar

28. Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med. 2004;10(2):145-7.10.1038/nm988 Search in Google Scholar

29. Inai T, Mancuso M, Hashizume H, Baffert F, Haskell A, Baluk P, et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol. 2004;165(1):35-52.10.1016/S0002-9440(10)63273-7 Search in Google Scholar

30. Lee Y, El Andaloussi S, Wood MJ. Exosomes and microvesicles: extracellular vesicles for genetic information transfer and gene therapy. Hum Mol Genet. 2012;21(R1):R125-34.10.1093/hmg/dds31722872698 Search in Google Scholar

31. Padera TP, Stoll BR, Tooredman JB, Capen D, di Tomaso E, Jain RK. Pathology: cancer cells compress intratumour vessels. Nature. 2004;427(6976):695.10.1038/427695a14973470 Search in Google Scholar

32. Denekamp J. Review article: angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br J Radiol. 1993;66(783):181-96.10.1259/0007-1285-66-783-1817682469 Search in Google Scholar

33. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science. 1994;265(5178):1582-4.10.1126/science.75215397521539 Search in Google Scholar

34. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst. 1990;82(1):4-6.10.1093/jnci/82.1.41688381 Search in Google Scholar

35. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995;1(1):27-31.10.1038/nm0195-277584949 Search in Google Scholar

36. Folkman J. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med. 1995;333(26):1757-63.10.1056/NEJM1995122833326087491141 Search in Google Scholar

37. Bottaro DP, Liotta LA. Cancer: Out of air is not out of action. Nature. 2003;423(6940):593-5.10.1038/423593a Search in Google Scholar

38. Mizejewski GJ. Role of integrins in cancer: survey of expression patterns. Proc Soc Exp Biol Med. 1999;222(2):124-38.10.1046/j.1525-1373.1999.d01-122.x Search in Google Scholar

39. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol. 2000;18(5):1135-49.10.1200/JCO.2000.18.5.1135 Search in Google Scholar

40. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science. 1997;277(5322):55-60.10.1126/science.277.5322.55 Search in Google Scholar

41. Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis S, et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell. 1996;87(7):1171-80.10.1016/S0092-8674(00)81813-9 Search in Google Scholar

42. Tournaire R, Simon MP, le Noble F, Eichmann A, England P, Pouyssegur J. A short synthetic peptide inhibits signal transduction, migration and angiogenesis mediated by Tie2 receptor. EMBO Rep. 2004;5(3):262-7.10.1038/sj.embor.7400100 Search in Google Scholar

43. Salven P, Lymboussaki A, Heikkila P, Jaaskela-Saari H, Enholm B, Aase K, et al. Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors. Am J Pathol. 1998;153(1): 103-8.10.1016/S0002-9440(10)65550-2 Search in Google Scholar

44. Amioka T, Kitadai Y, Tanaka S, Haruma K, Yoshihara M, Yasui W, et al. Vascular endothelial growth factor-C expression predicts lymph node metastasis of human gastric carcinomas invading the submucosa. Eur J Cancer. 2002;38(10):1413-9.10.1016/S0959-8049(02)00106-5 Search in Google Scholar

45. Andre T, Kotelevets L, Vaillant JC, Coudray AM, Weber L, Prevot S, et al. Vegf, Vegf-B, Vegf-C and their receptors KDR, FLT-1 and FLT-4 during the neoplastic progression of human colonic mucosa. Int J Cancer. 2000;86(2):174-81.10.1002/(SICI)1097-0215(20000415)86:2<174::AID-IJC5>3.0.CO;2-E Search in Google Scholar

46. Boocock CA, Charnock-Jones DS, Sharkey AM, McLaren J, Barker PJ, Wright KA, et al. Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J Natl Cancer Inst. 1995;87(7):506-16.10.1093/jnci/87.7.506 Search in Google Scholar

47. Decaussin M, Sartelet H, Robert C, Moro D, Claraz C, Brambilla C, et al. Expression of vascular endothelial growth factor (VEGF) and its two receptors (VEGF-R1-Flt1 and VEGF-R2-Flk1/KDR) in non-small cell lung carcinomas (NSCLCs): correlation with angiogenesis and survival. J Pathol. 1999;188(4):369-77.10.1002/(SICI)1096-9896(199908)188:4<369::AID-PATH381>3.0.CO;2-X Search in Google Scholar

48. Furudoi A, Tanaka S, Haruma K, Kitadai Y, Yoshihara M, Chayama K, et al. Clinical significance of vascular endothelial growth factor C expression and angiogenesis at the deepest invasive site of advanced colorectal carcinoma. Oncology. 2002;62(2):157-66.10.1159/000048262 Search in Google Scholar

49. George ML, Tutton MG, Janssen F, Arnaout A, Abulafi AM, Eccles SA, et al. VEGF-A, VEGF-C, and VEGF-D in colorectal cancer progression. Neoplasia. 2001;3(5):420-7.10.1038/sj.neo.7900186 Search in Google Scholar

50. Gunningham SP, Currie MJ, Han C, Robinson BA, Scott PA, Harris AL, et al. The short form of the alternatively spliced flt-4 but not its ligand vascular endothelial growth factor C is related to lymph node metastasis in human breast cancers. Clin Cancer Res. 2000;6(11):4278-86. Search in Google Scholar

51. Hashimoto I, Kodama J, Seki N, Hongo A, Yoshinouchi M, Okuda H, et al. Vascular endothelial growth factor-C expression and its relationship to pelvic lymph node status in invasive cervical cancer. Br J Cancer. 2001;85(1):93-7.10.1054/bjoc.2001.1846 Search in Google Scholar

52. Hirai M, Nakagawara A, Oosaki T, Hayashi Y, Hirono M, Yoshihara T. Expression of vascular endothelial growth factors (VEGF-A/VEGF-1 and VEGF-C/VEGF-2) in postmenopausal uterine endometrial carcinoma. Gynecol Oncol. 2001;80(2):181-8.10.1006/gyno.2000.6056 Search in Google Scholar

53. Jussila L, Valtola R, Partanen TA, Salven P, Heikkila P, Matikainen MT, et al. Lymphatic endothelium and Kaposi’s sarcoma spindle cells detected by antibodies against the vascular endothelial growth factor receptor-3. Cancer Res. 1998;58(8):1599-604. Search in Google Scholar

54. Kinoshita J, Kitamura K, Kabashima A, Saeki H, Tanaka S, Sugimachi K. Clinical significance of vascular endothelial growth factor-C (VEGF-C) in breast cancer. Breast Cancer Res Treat. 2001;66(2):159-64.10.1023/A:1010692132669 Search in Google Scholar

55. Kurebayashi J, Otsuki T, Kunisue H, Mikami Y, Tanaka K, Yamamoto S, et al. Expression of vascular endothelial growth factor (VEGF) family members in breast cancer. Jpn J Cancer Res. 1999;90(9):977-81.10.1111/j.1349-7006.1999.tb00844.x Search in Google Scholar

56. Niki T, Iba S, Tokunou M, Yamada T, Matsuno Y, Hirohashi S. Expression of vascular endothelial growth factors A, B, C, and D and their relationships to lymph node status in lung adenocarcinoma. Clin Cancer Res. 2000;6(6):2431-9. Search in Google Scholar

57. Nishida N, Yano H, Komai K, Nishida T, Kamura T, Kojiro M. Vascular endothelial growth factor C and vascular endothelial growth factor receptor 2 are related closely to the prognosis of patients with ovarian carcinoma. Cancer. 2004;101(6):1364-74.10.1002/cncr.20449 Search in Google Scholar

58. Ohta Y, Shridhar V, Bright RK, Kalemkerian GP, Du W, Carbone M, et al. VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. Br J Cancer. 1999;81(1):54-61.10.1038/sj.bjc.6690650 Search in Google Scholar

59. O-charoenrat P, Rhys-Evans P, Eccles SA. Expression of vascular endothelial growth factor family members in head and neck squamous cell carcinoma correlates with lymph node metastasis. Cancer. 2001;92(3):556-68.10.1002/1097-0142(20010801)92:3<556::AID-CNCR1355>3.0.CO;2-Q Search in Google Scholar

60. Skobe M, Hawighorst T, Jackson DG, Prevo R, Janes L, Velasco P, et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med. 2001;7(2):192-8.10.1038/8464311175850 Search in Google Scholar

61. Yokoyama Y, Charnock-Jones DS, Licence D, Yanaihara A, Hastings JM, Holland CM, et al. Vascular endothelial growth factor-D is an independent prognostic factor in epithelial ovarian carcinoma. Br J Cancer. 2003;88(2):237-44.10.1038/sj.bjc.6600701237704312610509 Search in Google Scholar

62. Yonemura Y, Endo Y, Fujita H, Fushida S, Ninomiya I, Bandou E, et al. Role of vascular endothelial growth factor C expression in the development of lymph node metastasis in gastric cancer. Clin Cancer Res. 1999;5(7):1823-9. Search in Google Scholar

63. Kajita T, Ohta Y, Kimura K, Tamura M, Tanaka Y, Tsunezuka Y, et al. The expression of vascular endothelial growth factor C and its receptors in non-small cell lung cancer. Br J Cancer. 2001; 85(2):255-60.10.1054/bjoc.2001.1882236404211461086 Search in Google Scholar

64. Mousa SA, Lin HY, Tang HY, Hercbergs A, Luidens MK, Davis PJ. Modulation of angiogenesis by thyroid hormone and hormone analogues: implications for cancer management. Angiogenesis. 2014;17(3):463-9.10.1007/s10456-014-9418-524458693 Search in Google Scholar

65. Finetti F, Solito R, Morbidelli L, Giachetti A, Ziche M, Donnini S. Prostaglandin E2 regulates angiogenesis via activation of fibroblast growth factor receptor-1. J Biol Chem. 2008;283(4):2139-46.10.1074/jbc.M70309020018042549 Search in Google Scholar

66. Xu L, Stevens J, Hilton MB, Seaman S, Conrads TP, Veenstra TD, et al. COX-2 inhibition potentiates antiangiogenic cancer therapy and prevents metastasis in preclinical models. Sci Transl Med. 2014; 6(242):242ra84.10.1126/scitranslmed.3008455630999524964992 Search in Google Scholar

67. Butler GS, Connor AR, Sounni NE, Eckhard U, Morrison CJ, Noel A, et al. Degradomic and yeast 2-hybrid inactive catalytic domain substrate trapping identifies new membrane-type 1 matrix metalloproteinase (MMP14) substrates: CCN3 (Nov) and CCN5 (WISP2). Matrix Biol. 2017;59:23-38.10.1016/j.matbio.2016.07.00627471094 Search in Google Scholar

68. Chen PC, Cheng HC, Wang J, Wang SW, Tai HC, Lin CW, et al. Prostate cancer-derived CCN3 induces M2 macrophage infiltration and contributes to angiogenesis in prostate cancer microenvironment. Oncotarget. 2014;5(6):1595-608.10.18632/oncotarget.1570403923424721786 Search in Google Scholar

69. Lin Z, Natesan V, Shi H, Hamik A, Kawanami D, Hao C, et al. A novel role of CCN3 in regulating endothelial inflammation. J Cell Commun Signal. 2010;4(3):141-53.10.1007/s12079-010-0095-x294812121063504 Search in Google Scholar

70. Zhang C, van der Voort D, Shi H, Zhang R, Qing Y, Hiraoka S, et al. Matricellular protein CCN3 mitigates abdominal aortic aneurysm. J Clin Invest. 2016;126(4):1282-99.10.1172/JCI82337481112626974158 Search in Google Scholar

71. Andreuzzi E, Colladel R, Pellicani R, Tarticchio G, Cannizzaro R, Spessotto P, et al. The angiostatic molecule Multimerin 2 is processed by MMP-9 to allow sprouting angiogenesis. Matrix Biol. 2017;64:40-53.10.1016/j.matbio.2017.04.002 Search in Google Scholar

72. Colladel R, Pellicani R, Andreuzzi E, Paulitti A, Tarticchio G, Todaro F, et al. MULTIMERIN2 binds VEGF-A primarily via the carbohydrate chains exerting an angiostatic function and impairing tumor growth. Oncotarget. 2016;7(2):2022-37.10.18632/oncotarget.6515 Search in Google Scholar

73. Ali SH, O’Donnell AL, Balu D, Pohl MB, Seyler MJ, Mohamed S, et al. Estrogen receptor-alpha in the inhibition of cancer growth and angiogenesis. Cancer Res. 2000;60(24):7094-8. Search in Google Scholar

74. Kerbel RS. Tumor angiogenesis. N Engl J Med. 2008;358(19):2039-49.10.1056/NEJMra0706596 Search in Google Scholar

75. Pavlakovic H, Havers W, Schweigerer L. Multiple angiogenesis stimulators in a single malignancy: implications for anti-angiogenic tumour therapy. Angiogenesis. 2001;4(4):259-62.10.1023/A:1016045012466 Search in Google Scholar

76. Stack MS, Gately S, Bafetti LM, Enghild JJ, Soff GA. Angiostatin inhibits endothelial and melanoma cellular invasion by blocking matrix-enhanced plasminogen activation. Biochem J. 1999;340 (Pt 1):77-84.10.1042/bj3400077 Search in Google Scholar

77. Claesson-Welsh L, Welsh M, Ito N, Anand-Apte B, Soker S, Zetter B, et al. Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrin-binding motif RGD. Proc Natl Acad Sci U S A. 1998;95(10):5579-83.10.1073/pnas.95.10.5579 Search in Google Scholar

78. Lucas R, Holmgren L, Garcia I, Jimenez B, Mandriota SJ, Borlat F, et al. Multiple forms of angiostatin induce apoptosis in endothelial cells. Blood. 1998;92(12):4730-41. Search in Google Scholar

79. Kirsch M, Strasser J, Allende R, Bello L, Zhang J, Black PM. Angiostatin suppresses malignant glioma growth in vivo. Cancer Res. 1998;58(20):4654-9. Search in Google Scholar

80. Rehn M, Veikkola T, Kukk-Valdre E, Nakamura H, Ilmonen M, Lombardo C, et al. Interaction of endostatin with integrins implicated in angiogenesis. Proc Natl Acad Sci U S A. 2001;98(3): 1024-9.10.1073/pnas.98.3.1024 Search in Google Scholar

81. Wickstrom SA, Alitalo K, Keski-Oja J. Endostatin associates with integrin alpha5beta1 and caveolin-1, and activates Src via a tyrosyl phosphatase-dependent pathway in human endothelial cells. Cancer Res. 2002;62(19):5580-9. Search in Google Scholar

82. Dhanabal M, Ramchandran R, Volk R, Stillman IE, Lombardo M, Iruela-Arispe ML, et al. Endostatin: yeast production, mutants, and antitumor effect in renal cell carcinoma. Cancer Res. 1999;59(1):189-97. Search in Google Scholar

83. Olsson AK, Johansson I, Akerud H, Einarsson B, Christofferson R, Sasaki T, et al. The minimal active domain of endostatin is a heparinbinding motif that mediates inhibition of tumor vascularization. Cancer Res. 2004;64(24):9012-7.10.1158/0008-5472.CAN-04-2172 Search in Google Scholar

84. O’Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997;88(2):277-85.10.1016/S0092-8674(00)81848-6 Search in Google Scholar

85. Hansen-Algenstaedt N, Stoll BR, Padera TP, Dolmans DE, Hicklin DJ, Fukumura D, et al. Tumor oxygenation in hormone-dependent tumors during vascular endothelial growth factor receptor-2 blockade, hormone ablation, and chemotherapy. Cancer Res. 2000;60(16):4556-60. Search in Google Scholar

86. Helmlinger G, Endo M, Ferrara N, Hlatky L, Jain RK. Formation of endothelial cell networks. Nature. 2000;405(6783):139-41.10.1038/3501213210821260 Search in Google Scholar

87. McKeown SR. Defining normoxia, physoxia and hypoxia in tumours-implications for treatment response. Br J Radiol. 2014;87(1035):20130676.10.1259/bjr.20130676406460124588669 Search in Google Scholar

88. Eales KL, Hollinshead KE, Tennant DA. Hypoxia and metabolic adaptation of cancer cells. Oncogenesis. 2016;5:e190.10.1038/oncsis.2015.50472867926807645 Search in Google Scholar

89. Ayob AZ, Ramasamy TS. Cancer stem cells as key drivers of tumour progression. J Biomed Sci. 2018;25(1):20.10.1186/s12929-018-0426-4583895429506506 Search in Google Scholar

90. Brahimi-Horn MC, Chiche J, Pouyssegur J. Hypoxia and cancer. J Mol Med (Berl). 2007;85(12):1301-7.10.1007/s00109-007-0281-318026916 Search in Google Scholar

91. Harris AL. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer. 2002;2(1):38-47.10.1038/nrc70411902584 Search in Google Scholar

92. Ward JP. Oxygen sensors in context. Biochim Biophys Acta. 2008; 1777(1):1-14.10.1016/j.bbabio.2007.10.01018036551 Search in Google Scholar

93. Semenza GL. Hypoxia-inducible factors in physiology and medicine. Cell. 2012;148(3):399-408.10.1016/j.cell.2012.01.021343754322304911 Search in Google Scholar

94. Harada H, Inoue M, Itasaka S, Hirota K, Morinibu A, Shinomiya K, et al. Cancer cells that survive radiation therapy acquire HIF-1 activity and translocate towards tumour blood vessels. Nat Commun. 2012;3:783.10.1038/ncomms1786333798722510688 Search in Google Scholar

95. Semenza GL. The hypoxic tumor microenvironment: A driving force for breast cancer progression. Biochim Biophys Acta. 2016;1863(3): 382-91.10.1016/j.bbamcr.2015.05.036467803926079100 Search in Google Scholar

96. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003;3(10):721-32.10.1038/nrc118713130303 Search in Google Scholar

97. Lu X, Kang Y. Hypoxia and hypoxia-inducible factors: master regulators of metastasis. Clin Cancer Res. 2010;16(24):5928-35.10.1158/1078-0432.CCR-10-1360300502320962028 Search in Google Scholar

98. King HW, Michael MZ, Gleadle JM. Hypoxic enhancement of exosome release by breast cancer cells. BMC Cancer. 2012;12:421.10.1186/1471-2407-12-421348858422998595 Search in Google Scholar

99. Shao C, Yang F, Miao S, Liu W, Wang C, Shu Y, et al. Role of hypoxia-induced exosomes in tumor biology. Mol Cancer. 2018;17(1):120.10.1186/s12943-018-0869-y608700230098600 Search in Google Scholar

100. Kosaka N, Iguchi H, Hagiwara K, Yoshioka Y, Takeshita F, Ochiya T. Neutral sphingomyelinase 2 (nSMase2)-dependent exosomal transfer of angiogenic microRNAs regulate cancer cell metastasis. J Biol Chem. 2013;288(15):10849-59.10.1074/jbc.M112.446831362446523439645 Search in Google Scholar

101. Tadokoro H, Umezu T, Ohyashiki K, Hirano T, Ohyashiki JH. Exosomes derived from hypoxic leukemia cells enhance tube formation in endothelial cells. J Biol Chem. 2013;288(48):34343-51.10.1074/jbc.M113.480822384304924133215 Search in Google Scholar

102. Umezu T, Tadokoro H, Azuma K, Yoshizawa S, Ohyashiki K, Ohyashiki JH. Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1. Blood. 2014;124(25):3748-57.10.1182/blood-2014-05-576116426398325320245 Search in Google Scholar

103. Hsu YL, Hung JY, Chang WA, Lin YS, Pan YC, Tsai PH, et al. Hypoxic lung cancer-secreted exosomal miR-23a increased angiogenesis and vascular permeability by targeting prolyl hydroxylase and tight junction protein ZO-1. Oncogene. 2017;36(34):4929-42.10.1038/onc.2017.10528436951 Search in Google Scholar

104. Mao G, Liu Y, Fang X, Liu Y, Fang L, Lin L, et al. Tumor-derived microRNA-494 promotes angiogenesis in non-small cell lung cancer. Angiogenesis. 2015;18(3):373-82.10.1007/s10456-015-9474-526040900 Search in Google Scholar

105. Park JE, Tan HS, Datta A, Lai RC, Zhang H, Meng W, et al. Hypoxic tumor cell modulates its microenvironment to enhance angiogenic and metastatic potential by secretion of proteins and exosomes. Mol Cell Proteomics. 2010;9(6):1085-99.10.1074/mcp.M900381-MCP200287797220124223 Search in Google Scholar

106. Kore RA, Edmondson JL, Jenkins SV, Jamshidi-Parsian A, Dings RPM, Reyna NS, et al. Hypoxia-derived exosomes induce putative altered pathways in biosynthesis and ion regulatory channels in glioblastoma cells. Biochem Biophys Rep. 2018;14:104-13.10.1016/j.bbrep.2018.03.008598655129872742 Search in Google Scholar

107. Skog J, Wurdinger T, van Rijn S, Meijer DH, Gainche L, Sena-Esteves M, et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol. 2008;10(12):1470-6.10.1038/ncb1800342389419011622 Search in Google Scholar

108. Kucharzewska P, Christianson HC, Welch JE, Svensson KJ, Fredlund E, Ringner M, et al. Exosomes reflect the hypoxic status of glioma cells and mediate hypoxia-dependent activation of vascular cells during tumor development. Proc Natl Acad Sci U S A. 2013;110(18):7312-7.10.1073/pnas.1220998110364558723589885 Search in Google Scholar

109. Milia AF, Salis MB, Stacca T, Pinna A, Madeddu P, Trevisani M, et al. Protease-activated receptor-2 stimulates angiogenesis and accelerates hemodynamic recovery in a mouse model of hindlimb ischemia. Circ Res. 2002;91(4):346-52.10.1161/01.RES.0000031958.92781.9E12193468 Search in Google Scholar

110. Svensson KJ, Kucharzewska P, Christianson HC, Skold S, Lofstedt T, Johansson MC, et al. Hypoxia triggers a proangiogenic pathway involving cancer cell microvesicles and PAR-2-mediated heparin-binding EGF signaling in endothelial cells. Proc Natl Acad Sci U S A. 2011;108(32):13147-52.10.1073/pnas.1104261108315618421788507 Search in Google Scholar

111. Huang Z, Feng Y. Exosomes Derived From Hypoxic Colorectal Cancer Cells Promote Angiogenesis Through Wnt4-Induced beta-Catenin Signaling in Endothelial Cells. Oncol Res. 2017;25(5):651-61.10.3727/096504016X14752792816791784111827712599 Search in Google Scholar

112. Sruthi TV, Edatt L, Raji GR, Kunhiraman H, Shankar SS, Shankar V, et al. Horizontal transfer of miR-23a from hypoxic tumor cell colonies can induce angiogenesis. J Cell Physiol. 2018;233(4):3498-514.10.1002/jcp.2620228929578 Search in Google Scholar

113. Grange C, Tapparo M, Collino F, Vitillo L, Damasco C, Deregibus MC, et al. Microvesicles released from human renal cancer stem cells stimulate angiogenesis and formation of lung premetastatic niche. Cancer Res. 2011;71(15):5346-56.10.1158/0008-5472.CAN-11-024121670082 Search in Google Scholar

114. Burnley-Hall N, Willis G, Davis J, Rees DA, James PE. Nitrite-derived nitric oxide reduces hypoxia-inducible factor 1alpha-mediated extracellular vesicle production by endothelial cells. Nitric Oxide. 2017;63:1-12.10.1016/j.niox.2016.12.00528017872 Search in Google Scholar

115. Zhang G, Zhang Y, Cheng S, Wu Z, Liu F, Zhang J. CD133 positive U87 glioblastoma cells-derived exosomal microRNAs in hypoxia-versus normoxia-microenviroment. J Neurooncol. 2017;135(1):37-46.10.1007/s11060-017-2566-x28948499 Search in Google Scholar

116. Luga V, Zhang L, Viloria-Petit AM, Ogunjimi AA, Inanlou MR, Chiu E, et al. Exosomes mediate stromal mobilization of autocrine Wnt-PCP signaling in breast cancer cell migration. Cell. 2012;151(7):1542-56.10.1016/j.cell.2012.11.02423260141 Search in Google Scholar

117. Alvarez-Teijeiro S, Garcia-Inclan C, Villaronga MA, Casado P, Hermida-Prado F, Granda-Diaz R, et al. Factors Secreted by Cancer-Associated Fibroblasts that Sustain Cancer Stem Properties in Head and Neck Squamous Carcinoma Cells as Potential Therapeutic Targets. Cancers (Basel). 2018;10(9).10.3390/cancers10090334616270430227608 Search in Google Scholar

118. Calvo F, Ege N, Grande-Garcia A, Hooper S, Jenkins RP, Chaudhry SI, et al. Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts. Nat Cell Biol. 2013;15(6):637-46.10.1038/ncb2756383623423708000 Search in Google Scholar

119. Koczorowska MM, Tholen S, Bucher F, Lutz L, Kizhakkedathu JN, De Wever O, et al. Fibroblast activation protein-alpha, a stromal cell surface protease, shapes key features of cancer associated fibroblasts through proteome and degradome alterations. Mol Oncol. 2016;10(1):40-58.10.1016/j.molonc.2015.08.001552892426304112 Search in Google Scholar

120. Ramteke A, Ting H, Agarwal C, Mateen S, Somasagara R, Hussain A, et al. Exosomes secreted under hypoxia enhance invasiveness and stemness of prostate cancer cells by targeting adherens junction molecules. Mol Carcinog. 2015;54(7):554-65.10.1002/mc.22124470676124347249 Search in Google Scholar

121. Fiaschi T, Giannoni E, Taddei ML, Cirri P, Marini A, Pintus G, et al. Carbonic anhydrase IX from cancer-associated fibroblasts drives epithelial-mesenchymal transition in prostate carcinoma cells. Cell Cycle. 2013;12(11):1791-801.10.4161/cc.24902371313723656776 Search in Google Scholar

122. Giannoni E, Bianchini F, Masieri L, Serni S, Torre E, Calorini L, et al. Reciprocal activation of prostate cancer cells and cancer-associated fibroblasts stimulates epithelial-mesenchymal transition and cancer stemness. Cancer Res. 2010;70(17):6945-56.10.1158/0008-5472.CAN-10-078520699369 Search in Google Scholar

123. Maia J, Caja S, Strano Moraes MC, Couto N, Costa-Silva B. Exosome-Based Cell-Cell Communication in the Tumor Microenvironment. Front Cell Dev Biol. 2018;6:18.10.3389/fcell.2018.00018582606329515996 Search in Google Scholar

124. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407(6801):249-57.10.1038/3502522011001068 Search in Google Scholar

125. Yoon YJ, Kim DK, Yoon CM, Park J, Kim YK, Roh TY, et al. Egr-1 activation by cancer-derived extracellular vesicles promotes endothelial cell migration via ERK1/2 and JNK signaling pathways. PLoS One. 2014;9(12):e115170.10.1371/journal.pone.0115170426488225502753 Search in Google Scholar

126. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285(21):1182-6.10.1056/NEJM1971111828521084938153 Search in Google Scholar

127. Song YH, Warncke C, Choi SJ, Choi S, Chiou AE, Ling L, et al. Breast cancer-derived extracellular vesicles stimulate myofibroblast differentiation and pro-angiogenic behavior of adipose stem cells. Matrix Biol. 2017;60-61:190-205.10.1016/j.matbio.2016.11.008543889127913195 Search in Google Scholar

128. Al-Nedawi K, Meehan B, Kerbel RS, Allison AC, Rak J. Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR. Proc Natl Acad Sci U S A. 2009;106(10):3794-9.10.1073/pnas.0804543106265615919234131 Search in Google Scholar

129. Conigliaro A, Costa V, Lo Dico A, Saieva L, Buccheri S, Dieli F, et al. CD90+ liver cancer cells modulate endothelial cell phenotype through the release of exosomes containing H19 lncRNA. Mol Cancer. 2015;14:155.10.1186/s12943-015-0426-x453680126272696 Search in Google Scholar

130. Dickman CT, Lawson J, Jabalee J, MacLellan SA, LePard NE, Bennewith KL, et al. Selective extracellular vesicle exclusion of miR-142-3p by oral cancer cells promotes both internal and extracellular malignant phenotypes. Oncotarget. 2017;8(9):15252-66.10.18632/oncotarget.14862536248428146434 Search in Google Scholar

131. Lawson J, Dickman C, MacLellan S, Towle R, Jabalee J, Lam S, et al. Selective secretion of microRNAs from lung cancer cells via extracellular vesicles promotes CAMK1D-mediated tube formation in endothelial cells. Oncotarget. 2017;8(48):83913-24.10.18632/oncotarget.19996566356429137392 Search in Google Scholar

132. Schillaci O, Fontana S, Monteleone F, Taverna S, Di Bella MA, Di Vizio D, et al. Exosomes from metastatic cancer cells transfer amoeboid phenotype to non-metastatic cells and increase endothelial permeability: their emerging role in tumor heterogeneity. Sci Rep. 2017;7(1):4711.10.1038/s41598-017-05002-y549850128680152 Search in Google Scholar

133. Zhuang G, Wu X, Jiang Z, Kasman I, Yao J, Guan Y, et al. Tumour-secreted miR-9 promotes endothelial cell migration and angiogenesis by activating the JAK-STAT pathway. EMBO J. 2012;31(17):3513-23.10.1038/emboj.2012.183343378222773185 Search in Google Scholar

134. You B, Shan Y, Bao L, Chen J, Yang L, Zhang Q, et al. The biology and function of extracellular vesicles in nasopharyngeal carcinoma (Review). Int J Oncol. 2018;52(1):38-46.10.3892/ijo.2017.4202 Search in Google Scholar

135. Liu Y, Luo F, Wang B, Li H, Xu Y, Liu X, et al. STAT3-regulated exosomal miR-21 promotes angiogenesis and is involved in neoplastic processes of transformed human bronchial epithelial cells. Cancer Lett. 2016;370(1):125-35.10.1016/j.canlet.2015.10.01126525579 Search in Google Scholar

136. Zomer A, Maynard C, Verweij FJ, Kamermans A, Schafer R, Beerling E, et al. In Vivo imaging reveals extracellular vesicle-mediated phenocopying of metastatic behavior. Cell. 2015;161(5):1046-57.10.1016/j.cell.2015.04.042444814826000481 Search in Google Scholar

137. Kosaka N. Decoding the Secret of Cancer by Means of Extracellular Vesicles. J Clin Med. 2016;5(2).10.3390/jcm5020022477377826861408 Search in Google Scholar

138. Abak A, Abhari A, Rahimzadeh S. Exosomes in cancer: small vesicular transporters for cancer progression and metastasis, biomarkers in cancer therapeutics. PeerJ. 2018;6:e4763.10.7717/peerj.4763598300229868251 Search in Google Scholar

139. Al-Nedawi K, Meehan B, Micallef J, Lhotak V, May L, Guha A, et al. Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat Cell Biol. 2008;10(5):619-24.10.1038/ncb172518425114 Search in Google Scholar

140. Nazarenko I, Rana S, Baumann A, McAlear J, Hellwig A, Trendelenburg M, et al. Cell surface tetraspanin Tspan8 contributes to molecular pathways of exosome-induced endothelial cell activation. Cancer Res. 2010;70(4):1668-78.10.1158/0008-5472.CAN-09-247020124479 Search in Google Scholar

141. Deregibus MC, Cantaluppi V, Calogero R, Lo Iacono M, Tetta C, Biancone L, et al. Endothelial progenitor cell derived microvesicles activate an angiogenic program in endothelial cells by a horizontal transfer of mRNA. Blood. 2007;110(7):2440-8.10.1182/blood-2007-03-07870917536014 Search in Google Scholar

142. Gesierich S, Berezovskiy I, Ryschich E, Zoller M. Systemic induction of the angiogenesis switch by the tetraspanin D6.1A/CO-029. Cancer Res. 2006;66(14):7083-94.10.1158/0008-5472.CAN-06-039116849554 Search in Google Scholar

143. Thompson CA, Purushothaman A, Ramani VC, Vlodavsky I, Sanderson RD. Heparanase regulates secretion, composition, and function of tumor cell-derived exosomes. J Biol Chem. 2013;288(14):10093-9.10.1074/jbc.C112.444562361725023430739 Search in Google Scholar

144. Hood JL, San RS, Wickline SA. Exosomes released by melanoma cells prepare sentinel lymph nodes for tumor metastasis. Cancer Res. 2011;71(11):3792-801.10.1158/0008-5472.CAN-10-445521478294 Search in Google Scholar

145. Gajos-Michniewicz A, Duechler M, Czyz M. MiRNA in melanoma-derived exosomes. Cancer Lett. 2014;347(1):29-37.10.1016/j.canlet.2014.02.00424513178 Search in Google Scholar

146. Umezu T, Ohyashiki K, Kuroda M, Ohyashiki JH. Leukemia cell to endothelial cell communication via exosomal miRNAs. Oncogene. 2013;32(22):2747-55.10.1038/onc.2012.29522797057 Search in Google Scholar

147. Zhou W, Fong MY, Min Y, Somlo G, Liu L, Palomares MR, et al. Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis. Cancer Cell. 2014;25(4):501-15.10.1016/j.ccr.2014.03.007401619724735924 Search in Google Scholar

148. Zitvogel L, Regnault A, Lozier A, Wolfers J, Flament C, Tenza D, et al. Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat Med. 1998;4(5):594-600.10.1038/nm0598-5949585234 Search in Google Scholar

149. Tominaga N, Kosaka N, Ono M, Katsuda T, Yoshioka Y, Tamura K, et al. Brain metastatic cancer cells release microRNA-181c-containing extracellular vesicles capable of destructing blood-brain barrier. Nat Commun. 2015;6:6716.10.1038/ncomms7716439639425828099 Search in Google Scholar

150. Treps L, Perret R, Edmond S, Ricard D, Gavard J. Glioblastoma stem-like cells secrete the pro-angiogenic VEGF-A factor in extracellular vesicles. J Extracell Vesicles. 2017;6(1):1359479.10.1080/20013078.2017.1359479554984628815003 Search in Google Scholar

151. Peinado H, Aleckovic M, Lavotshkin S, Matei I, Costa-Silva B, Moreno-Bueno G, et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med. 2012;18(6):883-91.10.1038/nm.2753364529122635005 Search in Google Scholar

152. Fabbri M, Paone A, Calore F, Galli R, Gaudio E, Santhanam R, et al. MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response. Proc Natl Acad Sci U S A. 2012;109(31): E2110-6.10.1073/pnas.1209414109341200322753494 Search in Google Scholar

153. Jabalee J, Towle R, Garnis C. The Role of Extracellular Vesicles in Cancer: Cargo, Function, and Therapeutic Implications. Cells. 2018;7(8).10.3390/cells7080093611599730071693 Search in Google Scholar

154. McCready J, Sims JD, Chan D, Jay DG. Secretion of extracellular hsp90alpha via exosomes increases cancer cell motility: a role for plasminogen activation. BMC Cancer. 2010;10:294.10.1186/1471-2407-10-294308731820553606 Search in Google Scholar

155. Gopal SK, Greening DW, Hanssen EG, Zhu HJ, Simpson RJ, Mathias RA. Oncogenic epithelial cell-derived exosomes containing Rac1 and PAK2 induce angiogenesis in recipient endothelial cells. Oncotarget. 2016;7(15):19709-22.10.18632/oncotarget.7573499141326919098 Search in Google Scholar

156. Hood JL, Pan H, Lanza GM, Wickline SA, Consortium for Translational Research in Advanced I, Nanomedicine. Paracrine induction of endothelium by tumor exosomes. Lab Invest. 2009; 89(11):1317-28.10.1038/labinvest.2009.94331648519786948 Search in Google Scholar

157. El-Kenawi AE, El-Remessy AB. Angiogenesis inhibitors in cancer therapy: mechanistic perspective on classification and treatment rationales. Br J Pharmacol. 2013;170(4):712-29.10.1111/bph.12344379958823962094 Search in Google Scholar

158. Teicher BA. A systems approach to cancer therapy. (Antioncogenics + standard cytotoxics->mechanism(s) of interaction). Cancer Metastasis Rev. 1996;15(2):247-72.10.1007/BF004374798842498 Search in Google Scholar

159. Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer. 2007;96(12):1788-95.10.1038/sj.bjc.6603813235996217519900 Search in Google Scholar

160. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9(6):669-76.10.1038/nm0603-66912778165 Search in Google Scholar

161. Gelinas DS, Bernatchez PN, Rollin S, Bazan NG, Sirois MG. Immediate and delayed VEGF-mediated NO synthesis in endothelial cells: role of PI3K, PKC and PLC pathways. Br J Pharmacol. 2002; 137(7):1021-30.10.1038/sj.bjp.0704956157357912429574 Search in Google Scholar

162. Hood JD, Meininger CJ, Ziche M, Granger HJ. VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am J Physiol. 1998;274(3 Pt 2):H1054-8.10.1152/ajpheart.1998.274.3.H10549530221 Search in Google Scholar

163. Sane DC, Anton L, Brosnihan KB. Angiogenic growth factors and hypertension. Angiogenesis. 2004;7(3):193-201.10.1007/s10456-004-2699-315609074 Search in Google Scholar

164. Bobrie A, Krumeich S, Reyal F, Recchi C, Moita LF, Seabra MC, et al. Rab27a supports exosome-dependent and -independent mechanisms that modify the tumor microenvironment and can promote tumor progression. Cancer Res. 2012;72(19):4920-30.10.1158/0008-5472.CAN-12-092522865453 Search in Google Scholar

165. Nishida-Aoki N, Tominaga N, Takeshita F, Sonoda H, Yoshioka Y, Ochiya T. Disruption of Circulating Extracellular Vesicles as a Novel Therapeutic Strategy against Cancer Metastasis. Mol Ther. 2017;25(1):181-91.10.1016/j.ymthe.2016.10.009536329728129113 Search in Google Scholar

166. Richards KE, Zeleniak AE, Fishel ML, Wu J, Littlepage LE, Hill R. Cancer-associated fibroblast exosomes regulate survival and proliferation of pancreatic cancer cells. Oncogene. 2017;36(13):1770-8.10.1038/onc.2016.353536627227669441 Search in Google Scholar

167. Agarwal S, Muniyandi P, Maekawa T, Kumar DS. Vesicular systems employing natural substances as promising drug candidates for MMP inhibition in glioblastoma: A nanotechnological approach. Int J Pharm. 2018;551(1-2):339-61.10.1016/j.ijpharm.2018.09.03330236647 Search in Google Scholar

168. Keller S, Sanderson MP, Stoeck A, Altevogt P. Exosomes: from biogenesis and secretion to biological function. Immunol Lett. 2006; 107(2):102-8.10.1016/j.imlet.2006.09.00517067686 Search in Google Scholar

169. Krause M, Samoylenko A, Vainio SJ. Exosomes as renal inductive signals in health and disease, and their application as diagnostic markers and therapeutic agents. Front Cell Dev Biol. 2015;3:65.10.3389/fcell.2015.00065461185726539435 Search in Google Scholar

170. Raposo G, Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol. 2013;200(4):373-83.10.1083/jcb.201211138357552923420871 Search in Google Scholar

171. Simons M, Raposo G. Exosomes-vesicular carriers for intercellular communication. Curr Opin Cell Biol. 2009;21(4):575-81.10.1016/j.ceb.2009.03.00719442504 Search in Google Scholar

172. Zhang X, Yuan X, Shi H, Wu L, Qian H, Xu W. Exosomes in cancer: small particle, big player. J Hematol Oncol. 2015;8:83.10.1186/s13045-015-0181-x449688226156517 Search in Google Scholar